Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche’s EU Accelerated Assessment Bid For Tumor Agnostic Entrectinib Backfires

Mar 04 2019

• By Alexandra Shimmings

Oxen — Unequally yoked: one indication holds back the other

Related Content

EU Accelerated Assessment Tracker 2018: Rejection Rates Remain High

Feb 28 2019

Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data

Sep 24 2018

FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer

Nov 27 2018

Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm

Oct 24 2018

Related Companies

Roche Holding AG

Bayer AG

Additional Topics

Companies Commercial Cancer BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window